Evidence map›Paper›PMID 34978399›Full record

ArticleTurkish journal of pharmaceutical sciences2021

Oyindamola Olajumoke Abiodun, Tolulope Aderinola Oke, Faridah Oyinkansola Adeyemi, Adedunke Omobolanle Oshinloye, Adesewa Omolola Akande

Open access · diamondAbstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Oyindamola Olajumoke AbiodunDepartment of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Ibadan, Nigeria.ORCID 0000-0002-6629-3016
Tolulope Aderinola OkeDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria.ORCID 0000-0002-0390-5847
Faridah Oyinkansola AdeyemiDepartment of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Ibadan, Nigeria.ORCID 0000-0001-9639-0872
Adedunke Omobolanle OshinloyeDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Federal University Oye-Ekiti, Oye-Ekiti, Nigeria.ORCID 0000-0002-2254-7635
Adesewa Omolola AkandeDepartment of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Ibadan, Nigeria.ORCID 0000-0001-7071-9318
University of Ibadan · NGFederal University Oye Ekiti · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesMATERIALS AND

methodsThe antioxidant property of

resultsSPL significantly scavenged free radical generated in the antioxidant assays and inhibited nitrite production in stimulated RAW 264.7 cells. Similarly, there was a 9-fold reduction in interleukin-6 produced in RAW 264.7 cells when exposed to the highest concentration of SPL. In addition, 50% lethal concentration of SPL was 455.58±82.35 µg/mL while cyclophosphamide gave 16.3±0.15 µg/mL in BSL test. Moreover, cell viability was not affected by SPL. Sixteen compounds were identified from SPL where thymol (29.79%), 3-carene (15.97%), and p-cymene (12.19%) are the most abundant.

conclusionMethanol extract of SPL showed antioxidant and anti-inflammatory activities by free radicals and cytokines inhibition. The activity observed may be related to the polyphenolic compounds in the plant.

Indexed as

Anti-inflammationantioxidantSalacia pallescens

Identifiers

PMID34978399
PMCPMC8744436
OpenAlexW3135502412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.